Cargando…

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies

Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tambasco, Nicola, Filidei, Marta, Nigro, Pasquale, Parnetti, Lucilla, Simoni, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706367/
https://www.ncbi.nlm.nih.gov/pubmed/34941718
http://dx.doi.org/10.3390/toxins13120881
_version_ 1784622175447154688
author Tambasco, Nicola
Filidei, Marta
Nigro, Pasquale
Parnetti, Lucilla
Simoni, Simone
author_facet Tambasco, Nicola
Filidei, Marta
Nigro, Pasquale
Parnetti, Lucilla
Simoni, Simone
author_sort Tambasco, Nicola
collection PubMed
description Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic condition, and spontaneous recovery is rare. Intramuscular injections of Botulinum Toxin (BoNT) are routinely used as HFS treatment. Methods: We reviewed published articles between 1991 and 2021 regarding the effectiveness and safety of BoNT in HFS as well as any reported differences among BoNT formulations. Results: The efficacy of BoNT for HFS treatment ranged from 73% to 98.4%. The mean duration of the effect was around 12 weeks. Effectiveness did not decrease over time. Adverse effects were usually mild and transient. The efficacy and tolerability of the different preparations appeared to be similar. Among the studies, dosage, injected muscles, intervals of treatment, and rating scales were variable, thus leading to challenges in comparing the results. Conclusions: BoNT was the treatment of choice for HFS due to its efficacy and safety profile. Further studies are needed to investigate the factors that influence the outcome, including the optimal timing of treatment, injection techniques, dosage, and the best selection criteria for formulations.
format Online
Article
Text
id pubmed-8706367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87063672021-12-25 Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies Tambasco, Nicola Filidei, Marta Nigro, Pasquale Parnetti, Lucilla Simoni, Simone Toxins (Basel) Review Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic condition, and spontaneous recovery is rare. Intramuscular injections of Botulinum Toxin (BoNT) are routinely used as HFS treatment. Methods: We reviewed published articles between 1991 and 2021 regarding the effectiveness and safety of BoNT in HFS as well as any reported differences among BoNT formulations. Results: The efficacy of BoNT for HFS treatment ranged from 73% to 98.4%. The mean duration of the effect was around 12 weeks. Effectiveness did not decrease over time. Adverse effects were usually mild and transient. The efficacy and tolerability of the different preparations appeared to be similar. Among the studies, dosage, injected muscles, intervals of treatment, and rating scales were variable, thus leading to challenges in comparing the results. Conclusions: BoNT was the treatment of choice for HFS due to its efficacy and safety profile. Further studies are needed to investigate the factors that influence the outcome, including the optimal timing of treatment, injection techniques, dosage, and the best selection criteria for formulations. MDPI 2021-12-09 /pmc/articles/PMC8706367/ /pubmed/34941718 http://dx.doi.org/10.3390/toxins13120881 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tambasco, Nicola
Filidei, Marta
Nigro, Pasquale
Parnetti, Lucilla
Simoni, Simone
Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title_full Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title_fullStr Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title_full_unstemmed Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title_short Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
title_sort botulinum toxin for the treatment of hemifacial spasm: an update on clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706367/
https://www.ncbi.nlm.nih.gov/pubmed/34941718
http://dx.doi.org/10.3390/toxins13120881
work_keys_str_mv AT tambasconicola botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies
AT filideimarta botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies
AT nigropasquale botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies
AT parnettilucilla botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies
AT simonisimone botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies